BioStock: Great progress for Iconovo's major investment ICOpre

Iconovo recently submitted the first two patent applications for ICOpre, the company’s latest inhalation platform and largest investment to date for the company. To optimise the development of ICOpre, Iconovo appointed Dr Kyrre Thalberg as Senior Advisor in formulation development. The activity around ICOpre comes as good sales results were presented for GSK’s Ellipta range of inhalation platforms, i.e. the inhalers that ICOpre is intended to mimic as a generic version.

Read the full article at biostock.se: 

https://www.biostock.se/en/great-progress-for-iconovos-major-investment-icopre/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se